- Home
- RIME vs PCSA Comparison
RIME vs PCSA Comparison
Compare RIME & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- PCSA
- Stock Information
- Founded
- RIME 1982
- PCSA 2011
- Country
- RIME United States
- PCSA United States
- Employees
- RIME N/A
- PCSA N/A
- Industry
- RIME
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- RIME
- PCSA Health Care
- Exchange
- RIME NYSE
- PCSA Nasdaq
- Market Cap
- RIME 1.4M
- PCSA 1.2M
- IPO Year
- RIME 1994
- PCSA N/A
- Fundamental
- Price
- RIME $2.40
- PCSA $0.24
- Analyst Decision
- RIME
- PCSA Strong Buy
- Analyst Count
- RIME 0
- PCSA 1
- Target Price
- RIME N/A
- PCSA $6.00
- AVG Volume (30 Days)
- RIME 113.2K
- PCSA 6.0M
- Earning Date
- RIME 04-16-2025
- PCSA 05-09-2025
- Dividend Yield
- RIME N/A
- PCSA N/A
- EPS Growth
- RIME N/A
- PCSA N/A
- EPS
- RIME N/A
- PCSA N/A
- Revenue
- RIME $23,494,000.00
- PCSA N/A
- Revenue This Year
- RIME N/A
- PCSA N/A
- Revenue Next Year
- RIME N/A
- PCSA N/A
- P/E Ratio
- RIME N/A
- PCSA N/A
- Revenue Growth
- RIME N/A
- PCSA N/A
- 52 Week Low
- RIME $1.71
- PCSA $0.22
- 52 Week High
- RIME $394.00
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- PCSA 32.80
- Support Level
- RIME N/A
- PCSA $0.20
- Resistance Level
- RIME N/A
- PCSA $0.25
- Average True Range (ATR)
- RIME 0.00
- PCSA 0.06
- MACD
- RIME 0.00
- PCSA 0.01
- Stochastic Oscillator
- RIME 0.00
- PCSA 33.54
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).